SA
NVO

Sovran Advisors’s Novo Nordisk NVO Stock Holding History

Sovran Advisors’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$538K Sell
10,550
-937
-8% -$40.3K 0.04% 369
2026
Q1 		$485K Buy
11,487
+1,527
+15% +$72.4K 0.04% 371
2025
Q4 		$569K Sell
9,960
-31,490
-76% -$1.61M 0.05% 320
2025
Q3 		$2.07M Buy
41,450
+520
+1% +$30.4K 0.18% 129
2025
Q2 		$2.85M Buy
40,930
+4,371
+12% +$297K 0.3% 95
2025
Q1 		$2.12M Buy
+36,559
New +$3.02M 0.28% 93

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Sovran Advisors's NVO Position: Q2 2026 in Review

Sovran Advisors reduced its Novo Nordisk (NVO) stake by 8.2% in Q2 2026, selling an estimated $40.3K and leaving 10,550 shares worth $538K. The position accounts for 0.04% of the portfolio, ranked #369.

Sovran Advisors first reported a position in NVO in Q1 2025 and has held it in 6 quarters since. The position peaked at $2.85M in Q2 2025. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Sovran Advisors held 10,550 shares of Novo Nordisk worth $538K as of Q2 2026.
  • Sovran Advisors sold 937 Novo Nordisk shares in Q2 2026, an estimated $40.3K.
  • Novo Nordisk made up 0.04% of Sovran Advisors's portfolio in Q2 2026, its #369 holding.
  • Sovran Advisors first reported a position in Novo Nordisk in Q1 2025 and has held it in 6 quarters since.
  • Sovran Advisors's Novo Nordisk position peaked at $2.85M in Q2 2025.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Sovran Advisors's 13F filing for Q2 2026, filed 30 Jul 2026.